Novartis $NVS has struck the latest in a series of deals to beef up its radiopharmaceuticals group.
Just weeks after the pharma giant snapped up Endocyte and its radioisotope drug Lu-PSMA-617 in a $2.1 billion deal — adding it to the Advanced Accelerator Applications group it acquired a little more than a year ago for $3.9 billion — its dealmaking crew has added global rights to a new radiopharmaceutical called FF-10158 for oncology indications.
There were no numbers in the deal with Fujifilm Toyama Chemical, but the pact clearly highlights Novartis’ eagerness to expand its work in this arena as fast as possible.
This new drug targets integrins, cell surface receptors found in cell membranes. And the Novartis team plans to use it in combination with their other drugs in this pipeline.
“Our goal is to develop radiopharmaceuticals that transform oncology treatment,” said Susanne Schaffert, the president of Advanced Accelerator Applications. “The in-licensing of FF-10158 expands our oncology theragnostic pipeline and we believe that this approach to integrating diagnostics and therapeutics has the potential to change patient management.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,000+ biopharma pros who read Endpoints News by email every day.Free Subscription